NCT00253890

Brief Summary

The purposes of this study are:

  1. 1.to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and
  2. 2.to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
137

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Oct 2005

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2005

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 10, 2005

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 15, 2005

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
3.6 years until next milestone

Results Posted

Study results publicly available

December 11, 2013

Completed
Last Updated

December 11, 2013

Status Verified

October 1, 2013

Enrollment Period

4.6 years

First QC Date

November 10, 2005

Results QC Date

August 1, 2012

Last Update Submit

October 22, 2013

Conditions

Keywords

sleep qualitymethadonesubstance use

Outcome Measures

Primary Outcomes (1)

  • Sleep Quality, as Measured by Total Sleep Time

    Number of minutes spent sleeping during sleep period, as measured by daily sleep diary.

    Baseline to 1-month

Study Arms (2)

Trazodone

ACTIVE COMPARATOR

50-150mg (50mg capsules) at bedtime for 90 days

Drug: Trazodone

Placebo

PLACEBO COMPARATOR

1-3 capsules at bedtime for 90 days

Drug: Placebo

Interventions

50 mg 1-3 capsules at bedtime for 3 months

Also known as: Desyrel, Oleptro, Beneficat, Deprax, Desirel, Molipaxin, Thombran, Trazorel, Trialodine, Trittico, Mesyrel
Trazodone

1-3 at bedtime

Also known as: Sugar pill
Placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Recent methadone maintenance enrollment
  • Sleep complaints as measured by the Pittsburgh Sleep Quality Index (PSQI)
  • No medical contraindications to trazodone

You may not qualify if:

  • Methadone maintenance enrollment not recent
  • No sleep complaints as measured by the PSQI
  • Medical contraindications to trazodone

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Butler Hospital

Providence, Rhode Island, 02906, United States

Location

Related Publications (1)

  • Kurth ME, Sharkey KM, Millman RP, Corso RP, Stein MD. Insomnia among methadone-maintained individuals: the feasibility of collecting home polysomnographic recordings. J Addict Dis. 2009 Jul;28(3):219-25. doi: 10.1080/10550880903014155.

MeSH Terms

Conditions

Opioid-Related DisordersSleep Initiation and Maintenance DisordersSubstance-Related Disorders

Interventions

TrazodoneSugars

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersChemically-Induced DisordersMental DisordersSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyridonesPyridinesCarbohydrates

Results Point of Contact

Title
Dr. Michael D. Stein, MD
Organization
Butler Hospital

Study Officials

  • Michael D Stein, MD

    Rhode Island Hospital

    PRINCIPAL INVESTIGATOR
  • Rogers Griffith, MD

    The Miriam Hospital

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, General Medicine Research

Study Record Dates

First Submitted

November 10, 2005

First Posted

November 15, 2005

Study Start

October 1, 2005

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

December 11, 2013

Results First Posted

December 11, 2013

Record last verified: 2013-10

Locations